Baili Tianheng's iza-bren late-stage triple-negative breast cancer Phase III clinical study achieved dual endpoints of PFS and OS

Recently, the globally first, innovative, and only EGFR×HER3 dual-target ADC (iza-bren) independently developed by BaiLi TianHeng has successfully achieved the predefined interim analysis for both PFS (Progression-Free Survival) and OS (Overall Survival) as dual primary endpoints in a Phase III clinical trial (Study Number: BL-B01D1-307) targeting locally advanced or metastatic triple-negative breast cancer (TNBC)